Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag bleeding-disorder

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

DECEMBER 12, 2022

Updated results from the ADVANCE IV study of Vyvgart (efgartigimod alfa) showed that more than half of patients with ITP treated with Argenx’ drug showed an improvement in platelet counts, which are dramatically reduced in the disorder. After 24 weeks, 21.8% After 24 weeks, 21.8% All told, 51.2%

Sales

Sales Trials Drugs Antibody

Hemgenix Approved as First Gene Therapy for Hemophilia B

XTalks

NOVEMBER 24, 2022

In a pivotal approval, the US Food and Drug Administration (FDA) has given the nod to a new gene therapy called Hemgenix (etranacogene dezaparvovecfor) for the treatment of adults with the genetic blood disorder hemophilia B (congenital Factor IX deficiency). With a list price of $3.5

Gene Therapy

Gene Therapy Gene FDA Approval Genetics

ASH: Argenx cues up a second use for efgartigimod

Hemgenix Approved as First Gene Therapy for Hemophilia B

Stay Connected